{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:42:28Z","timestamp":1785300148430,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Japanese Society of Hematology performed an observational cross-sectional study to clarify the morbidity, prognosis, and prognostic factors in patients with COVID-19 with hematological diseases (HDs) in Japan. The study included patients with HDs who enrolled in our epidemiological survey and had a COVID-19 diagnosis and a verified outcome of up to 2\u00a0months. The primary endpoints were characteristics and short-term prognosis of COVID-19 in patients with HDs. A total of 367 patients from 68 institutes were enrolled over 1\u00a0year, and the collected data were analyzed. The median follow-up among survivors was 73\u00a0days (range, 1\u2013639\u00a0days). The 60-day overall survival (OS) rate was 86.6%. In the multivariate analysis, albumin\u2009\u2264\u20093.3\u00a0g\/dL and a need for oxygen were independently associated with inferior 60-day OS rates (hazard ratio [HR] 4.026, 95% confidence interval (CI) 1.954\u20138.294 and HR 14.55, 95% CI 3.378\u201362.64, respectively), whereas 60-day survival was significantly greater in patients with benign rather than malignant disease (HR 0.095, 95% CI 0.012\u20130.750). Together, these data suggest that intensive treatment may be necessary for patients with COVID-19 with malignant HDs who have low albumin levels and require oxygen at the time of diagnosis.<\/jats:p>","DOI":"10.1007\/s12185-023-03685-w","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T18:02:22Z","timestamp":1704304942000},"page":"183-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characteristics and prognosis of patients with COVID-19 and hematological diseases in Japan: a cross-sectional study"],"prefix":"10.1007","volume":"119","author":[{"given":"Daisuke","family":"Minakata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nodoka","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Nakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki I.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9736-9469","authenticated-orcid":false,"given":"Kinuko","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"3685_CR1","unstructured":"https:\/\/data.who.int\/dashboards\/covid19\/cases. Accessed 31 July 2023."},{"key":"3685_CR2","doi-asserted-by":"publisher","first-page":"e3677","DOI":"10.1093\/cid\/ciaa1470","volume":"73","author":"N Matsunaga","year":"2021","unstructured":"Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, et al. Clinical epidemiology of hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan: report of the COVID-19 Registry Japan. Clin Infect Dis. 2021;73:e3677\u201389.","journal-title":"Clin Infect Dis"},{"key":"3685_CR3","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","volume":"34","author":"W He","year":"2020","unstructured":"He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34:1637\u201345.","journal-title":"Leukemia"},{"key":"3685_CR4","doi-asserted-by":"publisher","first-page":"5966","DOI":"10.1182\/bloodadvances.2020003170","volume":"4","author":"WA Wood","year":"2020","unstructured":"Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4:5966\u201375.","journal-title":"Blood Adv"},{"key":"3685_CR5","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1038\/s41409-020-0931-4","volume":"55","author":"F Malard","year":"2020","unstructured":"Malard F, Genthon A, Brissot E, van de Wyngaert Z, Marjanovic Z, Ikhlef S, et al. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 2020;55:2180\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"3685_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","volume":"14","author":"L Pagano","year":"2021","unstructured":"Pagano L, Salmanton-Garc\u00eda J, Marchesi F, Busca A, Corradini P, Hoenigl M, EPICOVIDEHA working group, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14:168.","journal-title":"J Hematol Oncol"},{"key":"3685_CR7","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","volume":"136","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881\u201392.","journal-title":"Blood"},{"key":"3685_CR8","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, ITA-HEMA-COV Investigators, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737\u201345.","journal-title":"Lancet Haematol."},{"key":"3685_CR9","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1111\/bjh.16801","volume":"190","author":"F Mart\u00edn-Moro","year":"2020","unstructured":"Mart\u00edn-Moro F, Marquet J, Piris M, Michael BM, S\u00e1ez AJ, Corona M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190:e16\u201320.","journal-title":"Br J Haematol"},{"key":"3685_CR10","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2020006000","volume":"135","author":"JM Connors","year":"2020","unstructured":"Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033\u201340.","journal-title":"Blood"},{"key":"3685_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.5551\/jat.RPT001","volume":"28","author":"H Horiuchi","year":"2021","unstructured":"Horiuchi H, Morishita E, Urano T, Yokoyama K, Questionnaire-survey Joint Team on The COVID-19-related thrombosis. COVID-19-related thrombosis in japan: final report of a questionnaire-based survey in 2020. J Atheroscler Thromb. 2021;28:406\u201316.","journal-title":"J Atheroscler Thromb"},{"key":"3685_CR12","unstructured":"Uchida T, Takagi Y, Mizuno A, Okamura H, Saito H, Ide S, et al. [Retrospective analysis of nosocomial COVID-19: a comparison between patients with hematological disorders and other diseases]. Rinsho Ketsueki. 2020;61:857\u2013864."},{"key":"3685_CR13","unstructured":"http:\/\/www.jshem.or.jp\/modules\/research\/index.php?content_id=2. Accessed 31 July 2023."},{"key":"3685_CR14","unstructured":"https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr\/ctr_view.cgi?recptno=R000049979. Accessed 31 July 2023."},{"key":"3685_CR15","unstructured":"Clinical Guide Version 9.0 (From ministry of health, labour and welfare (MHLW)) https:\/\/www.mhlw.go.jp\/content\/000936655.pdf. Accessed 31 July 2023."},{"key":"3685_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3685_CR17","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1056\/NEJMc2031670","volume":"383","author":"T Aydillo","year":"2020","unstructured":"Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383:2586\u20138.","journal-title":"N Engl J Med"},{"key":"3685_CR18","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","volume":"21","author":"LYW Lee","year":"2020","unstructured":"Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, UK Coronavirus Cancer Monitoring Project Team, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21:1309\u201316 (Erratum in: Lancet Oncol. 2020 Sep 3).","journal-title":"Lancet Oncol"},{"key":"3685_CR19","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1200\/JCO.20.01307","volume":"38","author":"J Jee","year":"2020","unstructured":"Jee J, Foote MB, Lumish M, Stonestrom AJ, Wills B, Narendra V, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol. 2020;38:3538\u201346.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3685_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13054-020-02995-3","volume":"24","author":"M Aziz","year":"2020","unstructured":"Aziz M, Fatima R, Lee-Smith W, Assaly R. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care. 2020;24(1):255.","journal-title":"Crit Care"},{"issue":"3","key":"3685_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248358","volume":"16","author":"M Kheir","year":"2021","unstructured":"Kheir M, Saleem F, Wang C, Mann A, Chua J. Higher albumin levels on admission predict better prognosis in patients with confirmed COVID-19. PLoS ONE. 2021;16(3): e0248358.","journal-title":"PLoS ONE"},{"issue":"1","key":"3685_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jmv.26232","volume":"93","author":"B Hu","year":"2021","unstructured":"Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250\u20136.","journal-title":"J Med Virol"},{"key":"3685_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, MOVe-OUT Study Group, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509\u201320.","journal-title":"N Engl J Med"},{"key":"3685_CR24","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, EPIC-HR Investigators, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397\u2013408.","journal-title":"N Engl J Med"},{"key":"3685_CR25","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, COMET-ICE Investigators, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941\u201350.","journal-title":"N Engl J Med"},{"key":"3685_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2021.24939","volume":"327","author":"MP O'Brien","year":"2022","unstructured":"O\u2019Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, COVID-19 Phase 3 Prevention Trial Team, et al. Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial. JAMA. 2022;327:432\u201341 (Erratum in: JAMA. 2022;327:2024).","journal-title":"JAMA"},{"key":"3685_CR27","doi-asserted-by":"publisher","first-page":"n2400","DOI":"10.1136\/bmj.n2400","volume":"375","author":"M Sholzberg","year":"2021","unstructured":"Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, \u00c1inle FN, RAPID trial investigators, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:n2400.","journal-title":"BMJ"},{"key":"3685_CR28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s12185-022-03305-z","volume":"115","author":"K Narita","year":"2022","unstructured":"Narita K, Nakaji S, Tabata R, Terao T, Kuzume A, Tsushima T, et al. Antibody response to COVID-19 vaccination in patients with lymphoma. Int J Hematol. 2022;115:728\u201336.","journal-title":"Int J Hematol"},{"key":"3685_CR29","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, PROVENT Study Group, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386:2188\u2013200.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03685-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03685-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03685-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T14:33:58Z","timestamp":1706711638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03685-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["3685"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03685-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"20 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IM (ONO PHARMACEUTICAL CO., LTD., Janssen Pharmaceutical K.K, NIPPON SHINYAKU CO., LTD., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd, Shionogi & Co., Ltd., TEIJIN PHARMA LIMITED, Boehringer Ingelheim, Sanofi, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., MSD K.K, ASAHI KASEI PHARMA CORPORATION), KM (Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K, TEIJIN PHARMA LIMITED., NIPPON SHINYAKU CO., LTD., TAIHO PHARMACEUTICAL CO., LTD., Takeda Pharmaceutical Company Limited., Otsuka Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and DAIICHI SANKYO COMPANY, LIMITED., Sumitomo Pharma Co., Ltd.) received grants or contracts from any entity. IM (Otsuka Pharmaceutical Co., Ltd), KM (Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Bristol\u2013Myers Squibb) received consulting fee of each company. DM (Janssen Pharmaceutical K.K), HK (Sanofi K.K., Bristol\u2013Meyrs Squibb, Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Novartis Japan, Janssen Pharmaceutical K.K., Takeda Pharamaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Japan Blood Products Organization, Daiichi Sankyo Co., Ltd., Glaxo-Smithkline K.K., AbbVie GK, Becton Dickinson Japan), HT (Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Mundi Pharm, Nippon Kayaku Co., Ltd., NIPPON SHINYAKU CO., LTD., Janssen Pharmaceutical K.K, Sanofi, Takeda Pharamaceutical Co., Ltd., Meiji Seika Pharm, Astra Zeneca, Bristol\u2013Meyrs Squibb, Ono Pharmaceutical Co.), IM (Bristol\u2013Myers Squibb, Novartis Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited., DAIICHI SANKYO COMPANY, LIMITED., ONO PHARMACEUTICAL CO., LTD., Chugai Pharmaceutical Co., Ltd., AstraZeneca, SymBio Pharmaceuticals, AbbVie GK, Amgen BioPharma K.K.), and KM (NIPPON SHINYAKU CO.,LTD., MSD K.K, Novartis Pharmaceuticals, Pfizer Japan Inc., Bristol\u2013Myers Squibb, Takeda Pharmaceutical Company Limited., Kyowa Kirin Co., Ltd., MOCHIDA PHARMACEUTICAL CO., LTD, AbbVie GK, Alexion Pharmaceuticals, Inc., ONO PHARMACEUTICAL CO., LTD., Otsuka Pharmaceutical Co., Ltd., Sanofi, Janssen Pharmaceutical K.K, SymBio Pharmaceuticals, AstraZeneka, Chugai Pharmaceutical Co., Ltd., CSL Behring, Amgen BioPharma K.K., Fujimoto Pharmaceutical Co., Eisai Co., Ltd., Sumitomo Pharma Co., Ltd., Meiji Seika Pharma, ASAHI KASEI PHARMA CORPORATION, Astellas Pharma Inc.) directly received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from any entity. KM (Kyowa Kirin Co., Ltd.) has received support for attending meetings and\/or travel. KM (Novartis Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Bristol\u2013Myers Squibb) participated on a data safety monitoring board or advisory board. TU, AN, KT, NT, EK, TN, TE, SN, HF, AS, TS, and KA have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}